Company: CDT
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001246
Chunk: 802

Company: CDT Equity Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 9B
Chunk 802
---
, agreed to a mutual non-disparagement covenant, and re-affirmed certain
confidentiality, non-solicitation and post-departure cooperation covenants.

79

Outstanding
Equity Awards at 2024 Fiscal Year-End

The
following table summarizes all of the outstanding equity-based awards held by our named executive officers as of December 31, 2024, the
end of our fiscal year. The option shares reported below have been adjusted to reflect the 1-for-100
reverse stock split on January 24, 2025.

    OPTION AWARDS
  
    NAME 
    OPTION OR STOCK AWARD GRANT DATE 
    NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS (#) EXERCISABLE  
    NUMBER OF SECURITIES UNDERLYING UNEXERCISED OPTIONS
(#) UNEXERCISABLE
  
    OPTION EXERCISE PRICE 
($)  
    OPTION EXPIRATION DATE
  
    David Tapolczay 
    11/18/2024(2)
     4,200  
     4,200  
    $9.20  
    11/17/2034

    12/1/2023(1)
     745  
     2,236  
     551  
    11/30/2033
  
    James Bligh 
    11/18/2024(2)
     9,450  
     9,450  
    $9.20  
    11/17/2034

    11/18/2024(1)
     559  
     1,677  
     551  
    11/30/2033

    (1)
    The
    stock option vests as to 1/4 of the underlying shares on each of the first four anniversaries of the vesting commencement date
  
    (2)
    The stock options vests 50% of the grant date and 50% in three equal annual installments thereafter

2023
Stock Incentive Plan

On
September 20, 2023, MURF stockholders approved the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (the “2023 Plan”).
The 2023 Plan permits our board of directors or compensation committee to grant may grant or issue stock options, stock appreciation
rights, restricted stock, restricted stock units,